In the mouse model of PDAC, SMO-independent GLI1 activation promotes transformation and requires both TGFβ and KRAS signaling (84) where inhibition of TGFβ by TbRI antagonist SD208 significantly reduces tumor burden and increases infiltration of lymphocytes. Here, GLI1 is linked to neoplasm.